Chemotherapy for three months demonstrates lower side effects, suggesting its use as standard care compared with six months.

The US FDA has approved Vyloy in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction cancer.

Tizona Therapeutics has expanded its ongoing Phase Ib clinical trial of TTX-080, HLA-G, in patients with biomarker-defined ...

Cantargia (Cantargia AB); today announced new clinical results from two nadunolimab combination therapy trials in 54 patients. Positive signals of efficacy were documented in the key areas of ...

In both studies, Vyloy was well-tolerated with the most common toxicities including nausea, vomiting and weakened appetite. In SPOTLIGHT, Vyloy was combined with mFOLFOX6—a treatment regimen that ...

The GLOW study compared zolbetuximab plus capecitabine and oxaliplatin (CAPOX) with placebo plus CAPOX. The SPOTLIGHT study compared zolbetuximab plus oxaliplatin, leucovorin and fluorouracil ...

However, the role of microRNA-582-3p in gastric cancer cells and its mechanism in the resistance of gastric cancer cells to oxaliplatin have not been studied. Methods: We first used q-PCR, CCK8, ...

Creating a Learning Health System in a Cancer Center: Generalizability of an Electronic Health Record Phenotype for Advanced Solid Cancer Breast cancer during pregnancy is uncommon; however, it is one ...

These include the taxanes, such as paclitaxel, often used to treat breast, ovarian, prostate and lung cancers; as well as alkylating agents, including oxaliplatin, used to treat colorectal, stomach or ...

All medicines have risks and benefits. Your doctor has weighed the risks of you using oxaliplatin against the benefits they expect it will have for you. If you have any concerns about taking this ...